Adjuvant kemoterapi uygulanmış meme kanserli hastalarda prognostik faktörler
Küçük Resim Yok
Tarih
2004
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Meme kanseri önemli bir sağlık sorunu haline gelmiştir. Tedavi seçeneklerini en uygun şekilde kullanmak için bir çok prognostik ve prediktif faktör üzerinde yoğun olarak çalışılmaktadır. Bunlardan en önemlileri aksiller lenf nodu tutulumu, tümör çapı, hormon reseptör pozitifliği, p53 ve C-erbB2 onkoprotein varlığıdır. Biz çalışmamızda bu prognostik faktörlerin, opere meme kanseri tanısı ile adjuvant AC (Adriamisin-siklofosfamid) kemoterapisi almış hastalarımızda etkilerini araştırdık. Hastalar ortalama dört yıl süreyle takip edildi. İzlem süresinde 40 hastadan 5'inde metastaz tespit edildi. Kaplan-Meier yöntemi ile hastalıksız sağ kalım 2 yıl için %97.5, 4 yıl içinse %73.1 olarak hesaplandı. Hastalıksız sağ kalım ortalama 42.2 aydı. Log-rank ile yapılan subgrup sağ kalım anazlizinde ise p53 varlığının prognozu kötü yönde etkilediği tespit edildi. Diğer faktörlerin ise prognoz üzerine istatistiksel olarak anlamlı etkide bulunmadığı saptandı.
Breast cancer is an important health problem. Many prognostic and predictive factors are being intensively investigated to determine most appropriate treatment option for patients with breast cancer. The most important prognostic and predictive factors are axillary lymph node involvement, tumor size, hormone receptor status, c-erbB-2 and p53 expression. In this study, we have investigated impact of these prognostic factors on patient survival in patients with breast cancer who have received adjuvant AC (adriamycin, cyclophosphamide) chemotherapy. Median follow up time was 48 months. In this period, 5 patients had metastases. By Kaplan-Meier method, we have found that disease-free survival at two years was %97, at four years was %73.1. Median disease-free survival was 42.2 months. By log-rank method, we have found that p53 has negative impact on prognosis. This finding is compatible with current literature. Other factors were not found to be statistically important on prognosis.
Breast cancer is an important health problem. Many prognostic and predictive factors are being intensively investigated to determine most appropriate treatment option for patients with breast cancer. The most important prognostic and predictive factors are axillary lymph node involvement, tumor size, hormone receptor status, c-erbB-2 and p53 expression. In this study, we have investigated impact of these prognostic factors on patient survival in patients with breast cancer who have received adjuvant AC (adriamycin, cyclophosphamide) chemotherapy. Median follow up time was 48 months. In this period, 5 patients had metastases. By Kaplan-Meier method, we have found that disease-free survival at two years was %97, at four years was %73.1. Median disease-free survival was 42.2 months. By log-rank method, we have found that p53 has negative impact on prognosis. This finding is compatible with current literature. Other factors were not found to be statistically important on prognosis.
Açıklama
Anahtar Kelimeler
Onkoloji
Kaynak
Türk Hematoloji Onkoloji Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
14
Sayı
3